Drug Shortage Report for MYOCHRYSINE
Report ID | 29274 |
Drug Identification Number | 01927604 |
Brand name | MYOCHRYSINE |
Common or Proper name | Myochrisine 50mg/1ml |
Company Name | SANOFI-AVENTIS CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | GOLD SODIUM THIOMALATE |
Strength(s) | 50MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging size | 5 |
ATC code | M01CB |
ATC description | SPECIFIC ANTIRHEUMATIC AGENTS |
Reason for shortage | Shortage of an active ingredient. |
Anticipated start date | 2017-11-24 |
Actual start date | 2017-12-01 |
Estimated end date | 2019-09-30 |
Actual end date | 2019-06-04 |
Shortage status | Resolved |
Updated date | 2019-06-10 |
Company comments | The continued global shortage of Myochrysine is due to manufacturing issues with the active ingredient. Consequently Sanofi has decided to discontinue all three strengths of Myochrysine globally. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.